A Case for the Adoption of Pharmacoeconomic Guidelines in Japan
- 28 Downloads
In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government. following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because. by doing so. they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased.
The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced into the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.
KeywordsPharmacoeconomic Analysis Pharmaceutical Firm Health Econ Pharmacoeconomic Data Pharmaceutical Price
Unable to display preview. Download preview PDF.
- 1.Commonwealth Department of Human Services and Health.Guidelines for the pharmaceutical industry on preparation ofsubmissions to the pharmaceutical benefits advisory committee-including major submissions involving economic analyses.Canberra: Australian Government Publishing Service.Google Scholar
- 2.Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals:Canada. 1st ed. Ottawa: CCOHTA. Nov 1994Google Scholar
- 4.Inoue S. Kitazawa S. Oliver A. et al. Present situation of pharmacoeconomic evaluation by Japanese pharmaceutical companies(abstract P6]. First Annual International Meeting forthe Association for Pharmacoeconomics and Outcomes Research:1996 May 12; PhiladelphiaGoogle Scholar
- 6.The Ministry of Health and Welfare. Administrative Announcement; 30 September 1994. Tokyo: Ministry of Health andWelfare. 1994Google Scholar
- 10.Ikeda S. Noguchi N. Oliver A. et al. A review of pharmacoeconomic studies in Japan (abstract C27]. First AnnualInternational Meeting for the Association for Pharmacoeconomicsand Outcomes Research: 1996 May 12: PhiladelphiaGoogle Scholar
- 11.Moriga M. Ikeda S. Reich MR. An analysis of pharmacoeconomic studies in Japan [in Japanesel. Iryo Keizai Kenkyu 1995;2: 73–83Google Scholar
- 14.Drummond MF. Stoddart GL. Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press. 1987Google Scholar
- 15.Gold MR Siegel JE Russell LB et al editors. Cost-effectiveness in health and medicine. New York: Oxford University Press. 1996Google Scholar
- 16.Society of Japanese Pharmacopoeia. editor. Guidelines for the clinical evaluation for new drugs 1995 [in Japanese]. Tokyo: Yakuji Nippo. 1995Google Scholar